{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55v1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10025","date":"2021-01-08T19:32:32.242Z","role":"Publisher"},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10025","date":"2018-09-25T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_cc_el","type":"EvidenceLine","evidence":[{"id":"cggv:18e812ce-3c96-4834-9077-22e55e02a61d","type":"EvidenceLine","evidence":[{"id":"cggv:18e812ce-3c96-4834-9077-22e55e02a61d_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:0e49d84f-e2f2-4d99-89a1-ce4977647c82","type":"Cohort","allGenotypedSequenced":388,"alleleFrequency":0.07216494845360824,"evidence":[{"id":"cggv:18e812ce-3c96-4834-9077-22e55e02a61d_cc_evidence_item"}],"numWithVariant":28,"relatedCondition":{"id":"obo:MONDO_0019171"}},"controlCohort":{"id":"cggv:fa1899c9-98b6-4497-918a-b5c0f28912d0","type":"Cohort","allGenotypedSequenced":1380,"alleleFrequency":0.02681159420289855,"evidence":[{"id":"cggv:18e812ce-3c96-4834-9077-22e55e02a61d_cc_evidence_item"}],"numWithVariant":37},"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.000097,"statisticalSignificanceType":"","statisticalSignificanceValueType":"","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19841300","type":"dc:BibliographicResource","dc:abstract":"Genetic testing for long-QT syndrome (LQTS) has diagnostic, prognostic, and therapeutic implications. Hundreds of causative mutations in 12 known LQTS-susceptibility genes have been identified. Genetic testing that includes the 3 most commonly mutated genes is available clinically. Distinguishing pathogenic mutations from innocuous rare variants is critical to the interpretation of test results. We sought to quantify the value of mutation type and gene/protein region in determining the probability of pathogenicity for mutations.","dc:creator":"Kapa S","dc:date":"2009","dc:title":"Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants."},"rdfs:label":"1"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":1},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":1.5},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:74883627-5978-4230-b202-202aad271af9_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:3ef469eb-dc35-4506-b016-3b8e0ce78956","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":13,"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"SCD","sex":"Female","variant":{"id":"cggv:74883627-5978-4230-b202-202aad271af9_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:918ef2a6-b73c-45f1-ad97-2768263f3bce","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000335.5(SCN5A):c.5347G>A (p.Glu1783Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA019148"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/10377081","type":"dc:BibliographicResource","dc:abstract":"Congenital long-QT syndrome (LQTS) is an inherited condition of abnormal cardiac excitability characterized clinically by an increased risk of ventricular tachyarrhythmias. One form, LQT3, is caused by mutations in the cardiac voltage-dependent sodium channel gene, SCN5A. Only 5 SCN5A mutations have been associated with LQTS, and more work is needed to improve correlations between SCN5A genotypes and associated clinical syndromes.","dc:creator":"Wei J","dc:date":"1999","dc:title":"Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10377081","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"cggv:bb190871-77bd-4d85-a266-11c40acc2df1_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c93f4c92-e00d-48e5-b7a4-90f50fecc5e2","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":17,"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Syncope, VT (no further details)","phenotypes":"obo:HP_0001657","sex":"Female","variant":{"id":"cggv:bb190871-77bd-4d85-a266-11c40acc2df1_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:918ef2a6-b73c-45f1-ad97-2768263f3bce"},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24871449","type":"dc:BibliographicResource","dc:abstract":"Genetic testing for long QT syndrome (LQTS) is now in clinical practice. We conducted molecular genetic analyses to definitively diagnose LQTS and to determine its subtypes for gene-specific treatment. We conducted a retrospective study to determine the characteristics of schoolchildren with LQTS living on the Okinawa Islands.","dc:creator":"Takahashi K","dc:date":"2014","dc:title":"High prevalence of the SCN5A E1784K mutation in school children with long QT syndrome living on the Okinawa islands."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24871449","rdfs:label":"Table 4: #2"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5,"dc:description":"Variant studied extensively, reported in multiple individuals with LQTS and absent from gnomAD"},{"id":"cggv:4acc5169-8f8e-4912-ac2b-167426b7c9b3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:e07990b8-3ad2-4826-8ee4-36bfb6b87dac","type":"Proband","sex":"Female","variant":{"id":"cggv:4acc5169-8f8e-4912-ac2b-167426b7c9b3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:918ef2a6-b73c-45f1-ad97-2768263f3bce"},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27566755","type":"dc:BibliographicResource","dc:abstract":"Risk stratification in patients with type 3 long-QT syndrome (LQT3) by clinical and genetic characteristics and effectiveness of β-blocker therapy has not been studied previously in a large LQT3 population.","dc:creator":"Wilde AA","dc:date":"2016","dc:title":"Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27566755","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5,"dc:description":"This publication includes a very large group of patients with pathogenic variants in this gene."}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":3.5},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:d6361cab-0a89-4c00-9c76-4e9801738581_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:9ab0dfc4-e53b-4312-b2a9-1fcda1a9c29d","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":16,"sex":"Male","variant":{"id":"cggv:d6361cab-0a89-4c00-9c76-4e9801738581_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:08a2abe7-8d04-40fd-9b87-abb5c2b8ea31","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000335.5(SCN5A):c.5293A>T (p.Met1765Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/446418"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12123767","type":"dc:BibliographicResource","dc:abstract":"Mutations in the cardiac sodium channel gene, SCN5A, cause congenital long QT syndrome (LQT3), Brugada syndrome, idiopathic ventricular fibrillation, and conduction disease by distinct cellular and clinical electrophysiological phenotypes.","dc:creator":"Valdivia CR","dc:date":"2002","dc:title":"A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/12123767","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:01855aab-9549-47da-bd67-3cf9cff12c68_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:0c13759b-bde6-41e7-9687-0bb158bf9857","type":"Proband","ageUnit":"Weeks","ageValue":9,"sex":"Male","variant":{"id":"cggv:01855aab-9549-47da-bd67-3cf9cff12c68_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:4104504d-9e47-4666-9a6b-905ce8eb7b18","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000335.5(SCN5A):c.3985G>C (p.Ala1329Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/67843"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/11535573","type":"dc:BibliographicResource","dc:abstract":"Congenital long QT syndrome (LQTS), a cardiac ion channel disease, is an important cause of sudden cardiac death. Prolongation of the QT interval has recently been associated with sudden infant death syndrome, which is the leading cause of death among infants between 1 week and 1 year of age. Available data suggest that early onset of congenital LQTS may contribute to premature sudden cardiac death in otherwise healthy infants.","dc:creator":"Wedekind H","dc:date":"2001","dc:title":"De novo mutation in the SCN5A gene associated with early onset of sudden infant death."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/11535573","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:8ad84d39-0cba-4b63-a011-95a3244615ac_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d64de483-8450-4cc1-9be3-758ae20a8ca6","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":14,"sex":"Male","variant":{"id":"cggv:8ad84d39-0cba-4b63-a011-95a3244615ac_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:3dc2c7d8-bce2-49c9-9712-31af7edc9994","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000335.5(SCN5A):c.5284G>A (p.Val1762Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/67974"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15485686","type":"dc:BibliographicResource","dc:abstract":"Congenital long QT syndrome (LQTS) with in utero onset of the rhythm disturbances is associated with a poor prognosis. In this study we investigated a newborn patient with fetal bradycardia, 2:1 atrioventricular block and ventricular tachycardia soon after birth.","dc:creator":"Chang CC","dc:date":"2004","dc:title":"A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15485686","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":6}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f6e6d06b-dd45-4333-beb2-dcc5439c0aa3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:eef2986f-93b9-40d4-8472-847ce7d36066","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Antisense complementary RNA probe identified in LV and RA","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/1309946","type":"dc:BibliographicResource","dc:abstract":"The principal voltage-sensitive sodium channel from human heart has been cloned, sequenced, and functionally expressed. The cDNA, designated hH1, encodes a 2016-amino acid protein that is homologous to other members of the sodium channel multigene family and bears greater than 90% identity to the tetrodotoxin-insensitive sodium channel characteristic of rat heart and of immature and denervated rat skeletal muscle. Northern blot analysis demonstrates an approximately 9.0-kilobase transcript expressed in human atrial and ventricular cardiac muscle but not in adult skeletal muscle, brain, myometrium, liver, or spleen. When expressed in Xenopus oocytes, hH1 exhibits rapid activation and inactivation kinetics similar to native cardiac sodium channels. The single channel conductance of hH1 to sodium ions is about twice that of the homologous rat channel and hH1 is more resistant to block by tetrodotoxin (IC50 = 5.7 microM). hH1 is also resistant to mu-conotoxin but sensitive to block by therapeutic concentrations of lidocaine in a use-dependent manner.","dc:creator":"Gellens ME","dc:date":"1992","dc:title":"Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel."},"rdfs:label":"northern blot"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:faaef053-f5f5-4417-858b-7683144f5f90","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ec9ab4e3-b99f-46a1-bcc5-b6ddb83faa0c","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Abnormal sodium channel function may lead to prolongation of APD which manifests as QT prolongation of surface ECG.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1309946","rdfs:label":"Patch clamp"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ca644b3f-75ab-4911-afc5-974166a8b191","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:fd4f5867-5af3-4c2d-a8dc-525fc3ea986d","type":"FunctionalAlteration","dc:description":"Sustained Na current","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/7651517","type":"dc:BibliographicResource","dc:abstract":"In the congenital long-QT syndrome, prolongation of the cardiac action potential occurs by an unknown mechanism and predisposes individuals to syncope and sudden death as a result of ventricular arrhythmias. Genetic heterogeneity has been demonstrated for autosomal dominant long-QT syndrome by the identification of multiple distinct loci, and associated mutations in two candidate genes have recently been reported. One form of hereditary long QT (LQT3) has been linked to a mutation in the gene encoding the human heart voltage-gated sodium-channel alpha-subunit (SCN5A on chromosome 3p21). Here we characterize this mutation using heterologous expression of recombinant human heart sodium channels. Mutant channels show a sustained inward current during membrane depolarization. Single-channel recordings indicate that mutant channels fluctuate between normal and non-inactivating gating modes. Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a molecular mechanism for this form of congenital long-QT syndrome.","dc:creator":"Bennett PB","dc:date":"1995","dc:title":"Molecular mechanism for an inherited cardiac arrhythmia."},"rdfs:label":"Patch clamping"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:1219972c-53ee-4245-a194-0e7b971eec1d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:76c68e7f-25f0-498d-833f-d0d0a880e739","type":"FunctionalAlteration","dc:description":"Faster recovery from inactivation, longer APD and EADs.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21799153","type":"dc:BibliographicResource","dc:abstract":"Current approaches for the investigation of long-QT syndromes (LQTS) are mainly focused on identification of the mutation and its characterization in heterologous expression systems. However, it would be extremely helpful to be able to characterize the pathophysiological effects of mutations and to screen drugs in cardiomyocytes.","dc:creator":"Malan D","dc:date":"2011","dc:title":"Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro."},"rdfs:label":"iPS"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:86a41cd4-4884-4d2a-bded-2c8c2cce98dd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:fb3b142a-3b99-4bf8-b7f4-f8bd7f017c31","type":"FunctionalAlteration","dc:description":"Delayed onset of inactivation and Isus","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17698727","type":"dc:BibliographicResource","dc:abstract":"Mexiletine (Mex) has been proposed as a gene-specific therapy for patients with long-QT syndrome type 3 (LQT3) caused by mutations in the cardiac sodium channel gene (SCN5A). The degree of QT shortening and the protection from arrhythmias vary among patients harboring different mutations. We tested whether the clinical response to Mex in LQT3 could be predicted by the biophysical properties of the different mutations.","dc:creator":"Ruan Y","dc:date":"2007","dc:title":"Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients."},"rdfs:label":"Whole-cell patch clamping"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:2b8731e6-c5bd-4bdb-9149-3e8f7ee5a98b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:873e37c2-6a2d-40b9-a513-575577ae9239","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"QT prolongation and pVT in 2/32 mice.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/11533705","type":"dc:BibliographicResource","dc:abstract":"Deletion of amino-acid residues 1505-1507 (KPQ) in the cardiac SCN5A Na(+) channel causes autosomal dominant prolongation of the electrocardiographic QT interval (long-QT syndrome type 3 or LQT3). Excessive prolongation of the action potential at low heart rates predisposes individuals with LQT3 to fatal arrhythmias, typically at rest or during sleep. Here we report that mice heterozygous for a knock-in KPQ-deletion (SCN5A(Delta/+)) show the essential LQT3 features and spontaneously develop life-threatening polymorphous ventricular arrhythmias. Unexpectedly, sudden accelerations in heart rate or premature beats caused lengthening of the action potential with early afterdepolarization and triggered arrhythmias in Scn5a(Delta/+) mice. Adrenergic agonists normalized the response to rate acceleration in vitro and suppressed arrhythmias upon premature stimulation in vivo. These results show the possible risk of sudden heart-rate accelerations. The Scn5a(Delta/+) mouse with its predisposition for pacing-induced arrhythmia might be useful for the development of new treatments for the LQT3 syndrome.","dc:creator":"Nuyens D","dc:date":"2001","dc:title":"Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome."},"rdfs:label":"Knock-in mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:abdb7acd-ef6d-4ecd-a4a8-98f90eff4fc9","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:6d529d2d-3592-49bd-b559-82344ac246df","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Prolongation of APD and VA similar ot QT prolongation and    TdP","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/14736542","type":"dc:BibliographicResource","dc:abstract":"Mutations in the cardiac sodium channel gene SCN5A are responsible for type-3 long QT disease (LQT3). The genesis of cardiac arrhythmias in LQT3 is multifaceted, and the aim of this study was to further explore mechanisms by which SCN5A mutations lead to arrhythmogenesis in vivo.","dc:creator":"Tian XL","dc:date":"2004","dc:title":"Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo."},"rdfs:label":"Transgenic mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":1797,"specifiedBy":"GeneValidityCriteria7","strengthScore":18,"subject":{"id":"cggv:af595223-e87f-4c12-8a4b-ade74a2b8e7b","type":"GeneValidityProposition","disease":"obo:MONDO_0019171","gene":"hgnc:10593","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","dc:description":"SCN5A encodes the alpha subunit of the cardiac voltage-gated sodium channel. Wang et al. were the first to identify variants in this gene using linkage analysis in families with LQTS (PMID 7889574). An abundance of experimental data which has accumulated over the decades since this publication demonstrates gain-of-function as the pathophysiological mechanism leading to QT prolongation in affected patients. A large body of genetic evidence, including segregation and case-control data, further supports the association of SCN5A with LQTS leading to classification of this association as definitive.  \nNote: All LQTS genes were curated by 3 separate blinded teams. The evidence and scores reached by these 3 teams were reviewed by the LQTS Clinical Domain Expert Panel. For a detailed discussion of this group's work and the separate scores of the 3 teams please see \"Adler et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation 2020;141(6):418-428. doi: 10.1161/CIRCULATIONAHA.119.043132”","dc:isVersionOf":{"id":"cggv:ab19e69c-50fb-41e3-8adf-4d27617f3d55"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}